Stemline Therapeutics Inc (NASDAQ:STML) Given Average Recommendation of “Buy” by Analysts

Stemline Therapeutics Inc (NASDAQ:STML) has earned a consensus recommendation of “Buy” from the eight analysts that are covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $22.50.

A number of analysts have recently weighed in on STML shares. Wedbush raised shares of Stemline Therapeutics from a “neutral” rating to an “outperform” rating in a research report on Friday. Roth Capital reaffirmed a “buy” rating on shares of Stemline Therapeutics in a research report on Thursday, May 23rd. ValuEngine downgraded shares of Stemline Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, May 15th. HC Wainwright set a $35.00 target price on shares of Stemline Therapeutics and gave the stock a “buy” rating in a research report on Thursday, June 20th. Finally, Zacks Investment Research raised shares of Stemline Therapeutics from a “hold” rating to a “buy” rating and set a $15.00 target price on the stock in a research report on Saturday, July 27th.

In related news, CEO Ivan Bergstein sold 56,316 shares of the company’s stock in a transaction dated Wednesday, June 26th. The shares were sold at an average price of $15.08, for a total value of $849,245.28. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, COO Kenneth Hoberman sold 25,817 shares of the company’s stock in a transaction dated Tuesday, May 14th. The stock was sold at an average price of $14.27, for a total transaction of $368,408.59. The disclosure for this sale can be found here. In the last quarter, insiders sold 149,177 shares of company stock worth $2,236,377. 13.10% of the stock is currently owned by company insiders.

Institutional investors and hedge funds have recently bought and sold shares of the business. BNP Paribas Arbitrage SA bought a new position in Stemline Therapeutics during the 1st quarter valued at about $102,000. Knott David M lifted its stake in shares of Stemline Therapeutics by 1.3% in the 1st quarter. Knott David M now owns 157,795 shares of the biopharmaceutical company’s stock worth $2,028,000 after purchasing an additional 2,000 shares during the period. Legal & General Group Plc lifted its stake in shares of Stemline Therapeutics by 27.1% in the 4th quarter. Legal & General Group Plc now owns 5,249 shares of the biopharmaceutical company’s stock worth $50,000 after purchasing an additional 1,120 shares during the period. Bank of America Corp DE lifted its stake in shares of Stemline Therapeutics by 56.8% in the 4th quarter. Bank of America Corp DE now owns 10,669 shares of the biopharmaceutical company’s stock worth $101,000 after purchasing an additional 3,866 shares during the period. Finally, Bank of New York Mellon Corp lifted its stake in shares of Stemline Therapeutics by 26.5% in the 4th quarter. Bank of New York Mellon Corp now owns 134,756 shares of the biopharmaceutical company’s stock worth $1,281,000 after purchasing an additional 28,198 shares during the period. Institutional investors and hedge funds own 78.79% of the company’s stock.

Stemline Therapeutics stock traded up $1.83 during mid-day trading on Friday, reaching $14.86. 1,545,962 shares of the company traded hands, compared to its average volume of 330,052. The company has a current ratio of 5.07, a quick ratio of 5.03 and a debt-to-equity ratio of 0.01. The stock’s 50 day moving average price is $14.19. Stemline Therapeutics has a 52-week low of $7.82 and a 52-week high of $17.85.

Stemline Therapeutics (NASDAQ:STML) last released its earnings results on Friday, August 2nd. The biopharmaceutical company reported ($0.42) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.47) by $0.05. The business had revenue of $13.01 million during the quarter, compared to analysts’ expectations of $8.84 million. Analysts predict that Stemline Therapeutics will post -2.09 EPS for the current fiscal year.

About Stemline Therapeutics

Stemline Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older.

Featured Story: What is quantitative easing?

Analyst Recommendations for Stemline Therapeutics (NASDAQ:STML)

Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.